Anticardiolipin antibodies do not mediate macrovascular complications of type 2 diabetes英文文献资料.docVIP

Open Journal of Internal Medicine, 2012, 2, 37-39 OJIM /10.4236/ojim.2012.21009 Published Online March 2012 (http://www.SciRP.org/journal/ojim/) Anticardiolipin antibodies do not mediate macrovascular complications of type 2 diabetes Caroline Eickhoff Copetti , Myriam Perreynoud , Melissa Claudia Bisi , Henrique Luiz Staub 1 2 1 1* 1 Rheumatology Department, S?o Lucas Hospital, Faculty of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil Clinical Pathology Laboratory, S?o Lucas Hospital, PUCRS, Porto Alegre, Brazil 2 Email: henriquestaub@.br * Received 7 September 2011; revised 11 November 2011; accepted 22 November 2011 ABSTRACT Anticardiolipin antibodies (ACA), as well as the lupus anticoagulant and antibodies to beta2-glycoprotein (beta2- gpI), are classical markers of the antiphospholipid syn- drome (APS) [1]. The relationship of ACA with vascular complications of diabetes is rather unclear. This cross-sectional study assessed the frequency of IgG, IgM, and IgA ACA in type 2 diabetics [2] with and without history of macrovascular events (myocardial and/or cerebral infarction) for the last 5 years, and in healthy controls. ACA were detected by enzyme immu- noassay (ORGENTEC Diagnostika GmbH—Anti-Car- diolipin). Titers were considered as positive when above 10 GPL for IgG ACA, 10 MPL for IgM ACA, and 7 units for IgA ACA [3]. The study was approved by the local ethics committee. Chi-square analysis were used for comparison of categorical variables, and the Student’s t test was used for comparison of continuous variables. A level of 5% (p 0.05) was considered significant. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated for univariate analysis. Logistic regress